A phase IIa study of tisotumab vedotin (HuMax®-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer

被引：0

作者：

Vergote, I. ^{[1
]}

Dean, E. ^{[2
]}

Lassen, U. ^{[3
]}

de Bono, J. ^{[4
]}

Drew, Y. ^{[5
]}

Machiels, J-P. ^{[6
]}

Nielsen, D. ^{[7
]}

Arkenau, H-T. ^{[8
]}

Forster, M. ^{[9
]}

Jones, R. ^{[10
]}

Slomovitz, B. ^{[11
]}

Spicer, J. ^{[12
]}

Johnson, M. ^{[13
]}

Cornez, N. ^{[14
]}

Gennigens, C. ^{[15
]}

Fulton, B. ^{[16
]}

Lisby, S. ^{[17
]}

Basse, L. ^{[18
]}

Coleman, R. ^{[19
]}

Hong, D. S. ^{[20
]}

机构：

[1] Univ Hosp Leuven, Gynaecol Verloskunde, Leuven, Belgium

[2] Christie NHS Fdn Trust, Clin Trials Unit, Manchester, Lancs, England

[3] Rigshosp, Dept Oncol, Phase Unit 1, Copenhagen, Denmark

[4] Royal Marsden Hosp, Inst Canc Res, Sect Med, Sutton, Surrey, England

[5] Newcastle Gen Hosp, Freeman Hosp, Northern Ctr Canc Treatment, Newcastle Upon Tyne, Tyne & Wear, England

[6] Roi Albert II, Oncol, Brussels, Belgium

[7] Herlev & Gentofte Hosp, Dept Oncol, Herlev, Denmark

[8] Sarah Cannon Res Inst SCRI UK, Oncol, London, England

[9] UCL, Canc Inst, Oncol, London, England

[10] Velindre Hosp, Velindre Canc Ctr, Oncol, Cardiff, S Glam, Wales

[11] Univ Miami, Miller Sch Med, Miami, FL 33136 USA

[12] Kings Coll London, Guys Hosp, Oncol, London, England

[13] Sarah Cannon Res Inst, Oncol, Nashville, TN USA

[14] Ctr Hosp Univ & Psychiat Mons Borinage, Oncol, Mons, Belgium

[15] Ctr Hosp Uuniv Sart Tilman, Oncol, Liege, Belgium

[16] Beatson West Scotland Canc Ctr, Oncol, Glasgow, Lanark, Scotland

[17] Genmab AS, Med Dept, Copenhagen, Denmark

[18] Genmab, Med Dept, Copenhagen, Denmark

[19] MD Anderson Canc Ctr, Oncol, Houston, TX USA

[20] Univ Texas MD Anderson Canc Ctr, Phase Unit 1, Houston, TX 77030 USA

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

931O

引用

页数：2

共 50 条

[1] A PHASE IIA STUDY OF TISOTUMAB VEDOTIN ((HuMax®-TF-ADC) IN PATIENTS WITH RELAPSED, RECURRENT AND/OR METASTATIC CERVICAL CANCER: UPDATED SAFETY AND EFFICACY
Concin, N.
Vergote, I.
Dean, E.
Lassen, U.
De Bono, J.
Drew, Y.
Machiels, J. P.
Nielsen, D.
Arkenau, T.
Forster, M.
Jones, R.
Slomovitz, B.
Spicer, J.
Johnsson, M.
Cornez, N.
Gennigens, C.
Fulton, B.
Rangwala, R.
Coleman, R.
Hong, D.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1971 - 1971
[2] A single arm, phase 2, multicenter, international trial of tisotumab vedotin (HuMax-TF-ADC) in previously treated, recurrent or metastatic cervical cancer.
Coleman, Robert L.
Concin, Nicole
Herzog, Thomas J.
Woelber, Linn Lena
Mirza, Mansoor Raza
Monk, Bradley J.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[3] A phase I/II safety study of tisotumab vedotin (HuMaxVR -TF-ADC) in patients with solid tumors
Chenard-Poirier, M.
Hong, D. S.
Coleman, R.
de Bono, J.
Mau-Sorensen, M.
Collins, D.
Lisby, S.
Basse, L.
Lassen, U.
ANNALS OF ONCOLOGY, 2017, 28
[4] Tisotumab vedotin in recurrent or metastatic cervical cancer
Bogani, Giorgio
Coleman, Robert L.
Vergote, Ignace
Raspagliesi, Francesco
Lorusso, Domenica
Monk, Bradley J.
CURRENT PROBLEMS IN CANCER, 2023, 47 (03)
[5] A phase IIa study of tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer: Updated analysis of full cervical expansion cohort
Concin, N.
Vergote, I. B.
Lassen, U. N.
Drew, Y.
Machiels, J-P.
Arkenau, H-T.
Forster, M. D.
Jones, R.
Johnson, M. L.
Slomovitz, B. M.
Spicer, J.
Cornez, N.
Gennigens, C.
Coleman, R. L.
Windfeld, K.
Ghatta, S.
Rangwala, R. A.
Hong, D. S.
ANNALS OF ONCOLOGY, 2018, 29 : 344 - 344
[6] Study Sees Encouraging Responses With Tisotumab Vedotin in Recurrent/Metastatic Cervical Cancer
不详
ONCOLOGY-NEW YORK, 2020, 34 (11): : 487 - 487
[7] Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer
Hong, David S.
Concin, Nicole
Vergote, Ignace
de Bono, Johann S.
Slomovitz, Brian M.
Drew, Yvette
Arkenau, Hendrik-Tobias
Machiels, Jean-Pascal
Spicer, James F.
Jones, Robert
Forster, Martin D.
Cornez, Nathalie
Gennigens, Christine
Johnson, Melissa L.
Thistlethwaite, Fiona C.
Rangwala, Reshma A.
Ghatta, Srinivas
Windfeld, Kristian
Harris, Jeffrey R.
Lassen, Ulrik Niels
Coleman, Robert L.
CLINICAL CANCER RESEARCH, 2020, 26 (06) : 1220 - 1228
[8] Tisotumab Vedotin-tftv Approved for Recurrent or Metastatic Cervical Cancer
Schuyler, Devon
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (10) : 649 - 649
[9] A Review of Tisotumab Vedotin-tftv in Recurrent or Metastatic Cervical Cancer
Heitz, Nathan
Greer, Samuel C.
Halford, Zachery
ANNALS OF PHARMACOTHERAPY, 2023, 57 (05) : 585 - 596
[10] Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study
Yonemori, Kan
Kuboki, Yasutoshi
Hasegawa, Kosei
Iwata, Takashi
Kato, Hidenori
Takehara, Kazuhiro
Hirashima, Yasuyuki
Kato, Hisamori
Passey, Chaitali
Buchbjerg, Jeppe Klint
Harris, Jeffrey R.
Andreassen, Camilla Mondrup
Nicacio, Leonardo
Soumaoro, Ibrahima
Fujiwara, Keiichi
CANCER SCIENCE, 2022, 113 (08) : 2788 - 2797

← 1 2 3 4 5 →